Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Open Access
- 15 August 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (16) , 5439-5446
- https://doi.org/10.1158/1078-0432.ccr-04-0218
Abstract
Purpose: Cisplatin is one of the most active agents for the treatment of non-small cell lung cancer (NSCLC). It is also known for significant toxicity, which makes it unsuitable for certain patients. Our purpose was to evaluate the efficacy and toxicity of a promising cisplatin-free combination, gemcitabine plus pemetrexed, in NSCLC.Keywords
This publication has 31 references indexed in Scilit:
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Clinical, toxicological and pharmacological aspects of gemcitabineCancer Treatment Reviews, 1996
- Preclinical characteristics of gemcitabineAnti-Cancer Drugs, 1995
- Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.Journal of Clinical Investigation, 1994
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958